And perhaps this one is listed overseas, which is what I glean from this hint:
“You have to do it in a way that might require a bit more work than simply calling your ordinary broker.”
And this is really the meat of the pitch, after Lashment talks for a bit about how much research he and Porter have put into companies that are working on cancer cures:
“And this year, we reached a stunning conclusion… and published some of our research in Porter’s monthly letter, Stansberry’s Investment Advisory.
“But there’s something else we discovered… that we’ve never published until now.
“And we believe it will change the way you think about cancer and potentially, help you make a small fortune in the months ahead.
“You see, working alongside one of the world’s most elite companies, that’s revolutionizing cancer care, we found a tiny firm founded by a handful of elite scientists, more than a dozen years ago…
“This firm has attracted very little attention from investors.
“Despite striking a deal with the larger firm… a deal worth potentially more than double its current market cap… that all but guarantees them hundreds of millions of dollars in revenue. If our analysis is correct… when this tiny company’s new cancer drug hits the market, early investors will profit from a royalty revenue stream worth hundreds of millions – even billions of dollars….
“… we’ve identified a giant company circling this tiny firm – that’s likely to swoop in and buy it out at a hugely inflated price.”
And as should be required for any commentary about early stage biotechs, it is, of course, risky and dependent on the outcome of uncertain clinical trials:
“The risk is not small. If their new drug doesn’t work, the company is a bust. In other words, you’re either going to make 5x… perhaps even 10x your money – or lose your entire stake.”
What else do we learn about this secret “Stansberry Venture #1?” Well, they like the clinical research team and the patent portfolio:
“The first thing we did was, confirm all their drug trials were funded, and all their doctors were best in class….
“An army of lawyers couldn’t break this tiny company’s patents, given a decade of effort. Their ‘monopoly’ is remarkably sound….”
And we do learn a little bit about the actual science of the drug, here’s a little taste of that:
“Cancer is a ‘master of disguise.’ Your body has the power to wipe it out… But the problem is – most of the time, it’s invisible….
“It shines a bright spotlight on cancer, so your body can detect it… then kill it off….
“Right now, we are standing at the threshold of one of the greatest quantum leaps in science – where a disease that kills nearly 600,000 Americans per year… could suddenly be rendered merely a chronic condition… instead of a death sentence.”
That’s the long way of saying this is an immunotherapy drug — and it does what many of these kinds of drugs do, it essentially finds a way to “flag” cancer cells so that your immune system can recognize them as unwanted and clobber them. They show some body scans demonstrating cancer remission, and share a couple stories of cancer immunotherapy success stories — though those are not actually stories connected to this “Stansberry Venture #1? stock, they’re clinical trial successes that were pretty well publicized in the last couple years.
A few more details to help us narrow it down?
“Right now, this tiny company’s immunotherapy drug is in human trials at one of the top cancer clinics in the
world, Memorial Sloan Kettering.
“Even better, it’s the only drug of its kind. No one else is working on anything like it…. this tiny company has produced something extremely valuable. A crucial, missing piece of the immunotherapy puzzle.
“… one big company has stepped up to foot the bill.
“According to one industry insider, it’s the largest funding deal of its kind….
“…the big drug company I’ve been telling you about has not only committed a 9-figure sum to accelerate this drug’s development… it has licensed it worldwide.
“And in doing so, it’s quietly agreed to pay this tiny firm much, much more:
“A massive, double-digit royalty on net sales of this new drug, worldwide.”
So that’s not necessarily enough to narrow it down to exactly one biotech stock… let’s look at it from the other angle, which is the big pharma stock that they think will take this company over?
Nice try---carry on
To .0003 then NO BID BMSN the WELFARE ATM of the "KOOS and CRONIES SYNDICATE"
AI
